Evidence map›Paper›PMID 31650375›Full record

ArticleAbdominal radiology (New York)2020

Association of tumor grade, enhancement on multiphasic CT and microvessel density in patients with clear cell renal cell carcinoma.

Heidi Coy, Jonathan R Young, Allan J Pantuck, Michael L Douek, Anthony Sisk, Clara Magyar, Matthew S Brown, James Sayre, Steven S Raman

Abstract read
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Heidi CoyDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, 924 Westwood Boulevard, Suite 615, Los Angeles, CA, 90024, USA. hcoy@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-4867-6723
Jonathan R YoungDepartment of Radiology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.
Allan J PantuckDepartment of Urology, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, 300 Stein Plaza, Room 346, BOX 957384, Los Angeles, CA, 90095, USA.
Michael L DouekDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, 924 Westwood Boulevard, Suite 615, Los Angeles, CA, 90024, USA.
Anthony SiskDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 12-229 CHS, Box 957437, Los Angeles, CA, 90095-1732, USA.
Clara MagyarDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 12-229 CHS, Box 957437, Los Angeles, CA, 90095-1732, USA.
Matthew S BrownDepartment of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine at UCLA, 924 Westwood Boulevard, Suite 650, Los Angeles, CA, 90024, USA.
James SayreDepartment of Biostatistics, UCLA School of Public Heath, Room 51-253A CHS/B3-116, Box 951772, Los Angeles, CA, 90095, USA.
Steven S RamanDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, 757 Westwood Plaza, RRUMC 1621H, Box 957437, Los Angeles, CA, 90095, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClear cell renal cell carcinoma (ccRCC) comprises nearly 90% of all diagnosed RCC subtypes and has the worst prognosis and highest metastatic potential. The strongest prognostic factors for patients with ccRCC include histological subtype and Fuhrman grade, which are incorporated into prognostic models. Since ccRCC is a highly vascularized tumor, there may be differences in enhancement patterns on multidetector CT (MDCT) due to the hemodynamics and microvessel density (MVD) of the lesions. This may provide a noninvasive method to characterize incidentally detected low- and high-grade ccRCCs on MDCT. The purpose of our study was to determine the correlation between MDCT enhancement parameters, ccRCC MVD, and Fuhrman grade to determine its utility and value in assessing tumor vascularity and grade in vivo.

methodsIn this retrospective, HIPAA-compliant, institutional review board-approved study with waiver of informed consent, 127 consecutive patients with 89 low-grade (LG), and 43 high-grade (HG) ccRCCs underwent preoperative four-phase MDCT. A 3D volume of interest (VOI) was obtained for every tumor and absolute enhancement and the wash-in/wash-out of enhancement for each phase was assessed. Immunohistochemistry on resected specimens was used to quantify MVD. Linear regression and Pearson correlation were used to investigate the strength of the association between 3D VOI enhancement and MVD. Stepwise logistic regression analysis determined independent predictors of HG ccRCC. Cut-off values and odds Ratio (OR) with 95% CIs were reported. The clinical, radiomic, and pathologic features with the highest performance in the stepwise logistic regression analysis were evaluated using receiver operator characteristics (ROC) and area under the curve (AUC).

resultsAbsolute enhancement in the nephrographic phase < 52.1 Hounsfield Units (HU) (HR 0.979, 95% CI 0.964-0.994, p value = 0.006), lesion size > 4.3 cm (HR 1.450, 95% CI 1.211-1.738, p value < 0.001), and an intratumoral MVD < 15% (HR 0.932, 95% CI 0.867-1.002, p value = 0.058) were independent predictors of HG ccRCC with an AUC of 0.818 (95% CI 0.725-0.911). HG ccRCCs had a significant association between 3D VOI enhancement and MVD in each post-contrast phase (r

conclusionsAbsolute enhancement of the entire lesion obtained from a 3D VOI in the nephrographic phase on preoperative MDCT can provide quantitative data that are a significant, independent predictor of a high-grade clear cell RCC and can be used to assess tumor vascularity and grade in vivo.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsDiagnosis, DifferentialHumansMicrovascular DensityMultidetector Computed TomographyRetrospective StudiesAngiogenesisClear cell RCCMicrovessel densityMultiphasic CTRadiomicsTumor grade

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.